Wird geladen...
Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma
The combination of CTLA-4 blockade ipilimumab (Ipi) with VEGF-A blocking antibody bevacizumab (Bev) has demonstrated favorable clinical outcomes in patients with advanced melanoma. Galectin-3 (Gal-3) plays a prominent role in tumor growth, metastasis, angiogenesis, and immune evasion. Here we report...
Gespeichert in:
| Veröffentlicht in: | Oncoimmunology |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Taylor & Francis
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5993498/ https://ncbi.nlm.nih.gov/pubmed/29900046 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1440930 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|